Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cerulean Shifts From Ovarian Cancer To Contraceptives In Reverse Merger With Daré

Executive Summary

Cerulean and privately-held Daré entered into a stock purchase agreement that will give the latter company's shareholders a majority stake in the combined company, which will focus on women's health – particularly contraceptives – instead of the former firm's nanoparticle-drug conjugates for cancer.

Advertisement

Related Content

Daré Bioscience On Prowl To Fill Gaps In Women's Sexual Health
Workforce Roundtable Part 3: Diversity And Progress – And Advice For Biopharma's Next Generation
Workforce Roundtable Part 2: Creating A 'Sticky' Workplace, Boardroom Roles For Women, Millennials
Workforce Roundtable Part 1: Recruiting Biopharma Leaders As The Talent Pool Shrinks And Diversifies
Depomed CEO, Two Board Members Out In Settlement With Investor
Deal Watch: BioLineRx, Ono, Vedantra Ink Separate Cancer Immunotherapy Pacts
Deal Watch: Novartis, Cerulean Team To Develop Nanoparticle-Drug Conjugates
Cerulean Slashes Jobs After Phase II Kidney Cancer Failure
TABLE: 2014 IPO values mixed at mid-year
Cypress finally succumbs to Ramius

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098449

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel